SG114194G - Tetrahydronaphthalene derivatives and medicaments containing them - Google Patents
Tetrahydronaphthalene derivatives and medicaments containing themInfo
- Publication number
- SG114194G SG114194G SG114194A SG114194A SG114194G SG 114194 G SG114194 G SG 114194G SG 114194 A SG114194 A SG 114194A SG 114194 A SG114194 A SG 114194A SG 114194 G SG114194 G SG 114194G
- Authority
- SG
- Singapore
- Prior art keywords
- alkyl
- dion
- benzodiazepine
- imidazo
- interrupted
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 title 1
- -1 tri-substituted 2-imidazolyl Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000004955 1,4-cyclohexylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:1])C([H])([H])C([H])([H])C1([H])[*:2] 0.000 abstract 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000005195 alkyl amino carbonyloxy group Chemical group 0.000 abstract 1
- 230000003288 anthiarrhythmic effect Effects 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 230000002213 calciumantagonistic effect Effects 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Luminescent Compositions (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Organic Insulating Materials (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG114194A SG114194G (en) | 1986-11-14 | 1994-08-13 | Tetrahydronaphthalene derivatives and medicaments containing them |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH456586 | 1986-11-14 | ||
| SG114194A SG114194G (en) | 1986-11-14 | 1994-08-13 | Tetrahydronaphthalene derivatives and medicaments containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG114194G true SG114194G (en) | 1994-11-25 |
Family
ID=4278454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG114194A SG114194G (en) | 1986-11-14 | 1994-08-13 | Tetrahydronaphthalene derivatives and medicaments containing them |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US4808605A (cs) |
| EP (1) | EP0268148B1 (cs) |
| JP (1) | JP2504490B2 (cs) |
| KR (1) | KR960004863B1 (cs) |
| CN (1) | CN1028991C (cs) |
| AT (1) | ATE70267T1 (cs) |
| AU (1) | AU600769B2 (cs) |
| BG (1) | BG60937B2 (cs) |
| CA (1) | CA1319144C (cs) |
| CS (2) | CS264350B2 (cs) |
| DE (2) | DE3775177D1 (cs) |
| DK (1) | DK171349B1 (cs) |
| DZ (1) | DZ1142A1 (cs) |
| ES (1) | ES2040234T3 (cs) |
| FI (1) | FI94414C (cs) |
| GR (1) | GR3004029T3 (cs) |
| HK (1) | HK110494A (cs) |
| HU (1) | HU215915B (cs) |
| IE (1) | IE60695B1 (cs) |
| IL (1) | IL84407A (cs) |
| LV (1) | LV5745B4 (cs) |
| MC (1) | MC1883A1 (cs) |
| MX (1) | MX173614B (cs) |
| NL (1) | NL970019I2 (cs) |
| NO (2) | NO172237C (cs) |
| NZ (1) | NZ222474A (cs) |
| PH (1) | PH23919A (cs) |
| PT (1) | PT86130B (cs) |
| SG (1) | SG114194G (cs) |
| ZA (1) | ZA878362B (cs) |
| ZW (1) | ZW20087A1 (cs) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2003283A1 (en) * | 1988-12-05 | 1990-06-05 | C. Anne Higley | Imidazoles for the treatment of atherosclerosis |
| CA2011461A1 (en) * | 1989-03-20 | 1990-09-20 | Urs Hengartner | Tetrahydronaphthalene derivatives |
| NL9001522A (nl) * | 1990-07-04 | 1992-02-03 | Schreiner Luchtvaart | Werkwijze voor het vervaardigen van een voorwerp bestaande uit een schuimkern en eventueel een of meer afdeklagen. |
| TW216770B (cs) * | 1991-07-23 | 1993-12-01 | Hoffmann La Roche | |
| US5565449A (en) * | 1991-10-18 | 1996-10-15 | Genentech, Inc. | Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor |
| US5250679A (en) * | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
| CN1088062C (zh) * | 1994-11-23 | 2002-07-24 | 纽罗根公司 | 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体 |
| ATE215108T1 (de) | 1995-06-23 | 2002-04-15 | Univ Delft Tech | Verfahren zur herstellung eines schäumbaren filmes |
| TR199700018A2 (tr) | 1996-01-31 | 1997-08-21 | Hoffmann La Roche | Alfa,beta-doymamis organik karboksilik asitlerin imaline yönelik proses. |
| US5811556A (en) * | 1997-04-30 | 1998-09-22 | Roche Colorado Corporation | Preparation of mibefradil via a naphthalenylacetic acid |
| US5811557A (en) * | 1997-04-30 | 1998-09-22 | Roche Colorado Corporation | Preparation of mibefradil via an acetonitrile anion |
| US5808088A (en) * | 1997-04-30 | 1998-09-15 | Roche Colorado Corporation | Preparation of mibefradil via an acetamide anion |
| US6897305B2 (en) * | 1998-06-08 | 2005-05-24 | Theravance, Inc. | Calcium channel drugs and uses |
| US7101909B2 (en) * | 1998-10-12 | 2006-09-05 | Theravance, Inc. | Calcium channel drugs and uses |
| MXPA02000927A (es) * | 1999-07-28 | 2003-07-14 | Johnson & Johnson | Amina y derivados de amida como ligandos para el receptor del neuropeptido y y5 utiles en el tratamiento de obesidad y otros trastornos. |
| AU2001235363A1 (en) * | 2000-02-25 | 2001-09-03 | Novo-Nordisk A/S | Mibefradil analogues and their use |
| WO2001062741A1 (en) * | 2000-02-25 | 2001-08-30 | South Alabama Medical Science Foundation | Tetrahydronaphtalene derivatives and their use |
| EP1156120B1 (en) * | 2000-05-08 | 2006-11-22 | Pfizer Products Inc. | Enzymatic resolution of selective estrogen receptor modulators |
| FR2827862A1 (fr) * | 2001-07-27 | 2003-01-31 | Lipha | Derives imidazolylalkylarylalcanoiques et leurs applications en therapeutique |
| CA2462913A1 (en) * | 2001-10-10 | 2003-04-17 | Aryx Therapeutics | Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina |
| KR20030037081A (ko) | 2001-11-02 | 2003-05-12 | 한국과학기술연구원 | Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법 |
| EP1545519B1 (en) | 2002-08-19 | 2011-03-23 | Pfizer Inc. | Combination therapy for hyperproliferative diseases |
| US20050037063A1 (en) * | 2003-07-21 | 2005-02-17 | Bolton Anthony E. | Combined therapies |
| CA2534228A1 (en) * | 2003-07-28 | 2005-02-10 | Janssen Pharmaceutica, N.V. | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators |
| AU2005269465A1 (en) * | 2004-07-26 | 2006-02-09 | Cotherix, Inc. | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| EP1951253A2 (en) | 2005-10-26 | 2008-08-06 | Cotherix, Inc. | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension |
| EP2351569B1 (en) | 2005-10-26 | 2012-08-22 | Asahi Kasei Pharma Corporation | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7919506B2 (en) | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| EP2094643B1 (en) | 2006-12-01 | 2012-02-29 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| TW200906396A (en) * | 2007-02-14 | 2009-02-16 | Janssen Pharmaceutica Nv | LTA4H modulators and uses thereof |
| CL2008001205A1 (es) * | 2007-04-27 | 2008-11-14 | Actelion Pharmaceuticals Ltd | Compuestos derivados de biciclo[2.2.2]octeno; composicion farmaceutica que los contiene; y uso en el tratamiento o prevencion de angina cronica estable, hipertension, isquemia renal y cardiaca, arritmias cardiacas, hipertrofia cardiaca y falla congestiva del corazon. |
| NZ588341A (en) * | 2008-04-11 | 2012-06-29 | Janssen Pharmaceutica Nv | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase |
| WO2009130679A1 (en) * | 2008-04-25 | 2009-10-29 | Actelion Pharmaceuticals Ltd | Benzimidazole derivatives as calcium channel blockers |
| CA2740430A1 (en) | 2008-10-22 | 2010-04-29 | Actelion Pharmaceuticals Ltd | Bridged tetrahydronaphthalene derivatives |
| WO2010046729A2 (en) * | 2008-10-23 | 2010-04-29 | Actelion Pharmaceuticals Ltd | Tetrahydronaphthalene compounds |
| CA3027255C (en) | 2009-07-10 | 2022-06-21 | The General Hospital Corporation | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
| EP3144296A1 (en) * | 2010-03-02 | 2017-03-22 | Concert Pharmaceuticals, Inc. | Deuterated tetrahydronaphthalene derivatives |
| US8575361B2 (en) | 2010-03-02 | 2013-11-05 | Concert Pharmaceuticals Inc. | Tetrahydronaphthalene derivatives |
| US8883844B2 (en) | 2010-09-24 | 2014-11-11 | Nitrogenix Inc. | Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions |
| CN105143203A (zh) | 2013-04-17 | 2015-12-09 | 辉瑞大药厂 | 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物 |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| WO2017070680A1 (en) | 2015-10-22 | 2017-04-27 | Cavion Llc | Methods for treating angelman syndrome and related disorders |
| WO2018152317A1 (en) * | 2017-02-15 | 2018-08-23 | Cavion, Inc. | Calcium channel inhibitors |
| JP7321097B2 (ja) | 2017-04-26 | 2023-08-04 | カビオン・インコーポレイテッド | 記憶および認知を改善する、ならびに記憶および認知障害を処置するための方法 |
| WO2020072773A1 (en) | 2018-10-03 | 2020-04-09 | Cavion, Inc. | Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
| ES3007652T3 (en) | 2019-01-18 | 2025-03-20 | Astrazeneca Ab | 6'-[[(1s,3s)-3-[[5-(difluoromethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-one as pcsk9 inhibitor and methods of use thereof |
| CN115850119A (zh) * | 2022-11-26 | 2023-03-28 | 南昌大学 | 一种2-氯芳香胺类化合物的合成方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3914216A (en) * | 1962-12-18 | 1975-10-21 | Boehringer Sohn Ingelheim | 1-Phenyl-3H-1,4-benzodiazepine-2,5-(1H,4H)-diones |
| BE793460A (fr) * | 1971-12-29 | 1973-06-28 | Boehringer Sohn Ingelheim | Nouvelles 1-aryl-3h,1,4-benzodiazepine-2,5-(1h |
| NZ213651A (en) * | 1984-10-11 | 1989-07-27 | Hoffmann La Roche | Tetrahydronapthalene derivatives and medicaments |
-
1987
- 1987-10-26 DK DK559987A patent/DK171349B1/da not_active IP Right Cessation
- 1987-10-26 CA CA000550190A patent/CA1319144C/en not_active Expired - Fee Related
- 1987-11-03 ZW ZW200/87A patent/ZW20087A1/xx unknown
- 1987-11-03 CS CS877874A patent/CS264350B2/cs not_active IP Right Cessation
- 1987-11-04 DE DE8787116251T patent/DE3775177D1/de not_active Expired - Lifetime
- 1987-11-04 ES ES198787116251T patent/ES2040234T3/es not_active Expired - Lifetime
- 1987-11-04 DE DE1997175076 patent/DE19775076I2/de active Active
- 1987-11-04 EP EP87116251A patent/EP0268148B1/de not_active Expired - Lifetime
- 1987-11-04 AT AT87116251T patent/ATE70267T1/de active
- 1987-11-06 NZ NZ222474A patent/NZ222474A/xx unknown
- 1987-11-06 ZA ZA878362A patent/ZA878362B/xx unknown
- 1987-11-09 AU AU80909/87A patent/AU600769B2/en not_active Ceased
- 1987-11-09 IL IL84407A patent/IL84407A/xx unknown
- 1987-11-10 JP JP62282287A patent/JP2504490B2/ja not_active Expired - Lifetime
- 1987-11-10 US US07/119,114 patent/US4808605A/en not_active Expired - Lifetime
- 1987-11-11 PH PH36056A patent/PH23919A/en unknown
- 1987-11-11 DZ DZ870191A patent/DZ1142A1/fr active
- 1987-11-11 HU HU875011A patent/HU215915B/hu not_active IP Right Cessation
- 1987-11-12 MX MX009271A patent/MX173614B/es unknown
- 1987-11-12 MC MC871928A patent/MC1883A1/xx unknown
- 1987-11-13 CN CN87107875A patent/CN1028991C/zh not_active Expired - Fee Related
- 1987-11-13 IE IE307087A patent/IE60695B1/en not_active IP Right Cessation
- 1987-11-13 FI FI875024A patent/FI94414C/fi not_active IP Right Cessation
- 1987-11-13 KR KR87012777A patent/KR960004863B1/ko not_active Expired - Fee Related
- 1987-11-13 PT PT86130A patent/PT86130B/pt not_active IP Right Cessation
- 1987-11-13 NO NO874757A patent/NO172237C/no not_active IP Right Cessation
-
1991
- 1991-12-20 CS CS913948A patent/CS394891A3/cs unknown
-
1992
- 1992-03-11 GR GR920400420T patent/GR3004029T3/el unknown
-
1994
- 1994-02-14 BG BG098469A patent/BG60937B2/bg unknown
- 1994-08-13 SG SG114194A patent/SG114194G/en unknown
- 1994-10-12 HK HK110494A patent/HK110494A/xx not_active IP Right Cessation
-
1996
- 1996-05-24 LV LV960155A patent/LV5745B4/xx unknown
-
1997
- 1997-05-27 NL NL970019C patent/NL970019I2/nl unknown
-
1998
- 1998-01-09 NO NO1998001C patent/NO1998001I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960004863B1 (en) | Tetrahydronaphthalene derivatives and its process | |
| IE900161L (en) | Pyrazolopyridines | |
| IE781478L (en) | IMIDAZO £2,1-b| QUINAZOLINES | |
| FI883807A7 (fi) | Menetelmä farmakologisesti aktiivisten 7-(3-substituoitu-1-pyrrolidinyyli)-1-syklopropyyli-1,4-dihydro-4-okso-1,8-naftyridiini-3-karboksyylihappojohdannaisten valmistamiseksi | |
| NO161971C (no) | Analogifremgangsmaate ved fremstilling av tetrahydronaftalinderivater. | |
| IE780119L (en) | IMIDAZO(1,2-a) QUINOLINE-2-CARBOXYLIC ACIDS | |
| KR890014112A (ko) | 퀴놀리진 및 퀴놀리지논 유도체의 심장 부정맥 치료용 의약품 제조에 있어서의 용도 | |
| IE44154L (en) | 1,3,8-triazaspiro(4,5) decan-4-one derivatives | |
| NO305655B1 (no) | Antiarytmiske og kardiobeskyttende substituerte indenoylguanidiner, deres anvendelse for fremstilling av legemidler, samt legemiddel inneholdende disse | |
| NO170488C (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive 3-alkoksy-5,6,7,8-tetrahydro-4h-isoksazolo (4,5-c) azepinderivater | |
| ZA867675B (en) | 2-(2-thienyl)-imidazo(4,5-c)pyridine derivatives and salts thereof,processes for their preparation and pharmaceutical products containing these | |
| JPS57131788A (en) | 1,7-naphthyridine derivative | |
| NO177786B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive pyrido-[2,3-bÅ-benzazepin- (og -tiazepin)-5(6H)-on-derivater | |
| JPS57131789A (en) | 1,7-naphthyridine derivative |